Design Therapeutics (DSGN) Change in Acquisitions & Divestments (2020 - 2026)

Design Therapeutics (DSGN) has 7 years of Change in Acquisitions & Divestments data on file, last reported at $45.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments fell 52.38% year-over-year to $45.0 million; the trailing twelve-month figure through Mar 2026 stood at $265.4 million (down 12.26% YoY), and the FY2025 full-year result was $314.9 million, up 14.72% from the prior year.
• Change in Acquisitions & Divestments retreated to $45.0 million in Q1 2026, from $76.1 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $94.5 million in Q1 2025 to a low of $490000.0 in Q1 2022.
• A 5-year average of $59.1 million and a median of $66.2 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• Peak annual rise in Change in Acquisitions & Divestments reached 30020.0% in 2022, while the deepest fall reached 98.26% in 2022.
• Tracing DSGN's Change in Acquisitions & Divestments over 5 years: stood at $60.2 million in 2022, then soared by 32.36% to $79.7 million in 2023, then dropped by 16.97% to $66.2 million in 2024, then advanced by 14.91% to $76.1 million in 2025, then tumbled by 40.85% to $45.0 million in 2026.
• Business Quant data shows DSGN's Change in Acquisitions & Divestments at $45.0 million in Q1 2026, $76.1 million in Q4 2025, and $84.6 million in Q3 2025.